Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria: Beacon Trial Design

George Mensing, Haley Howell, Katherine Chan, Brian MacDonald, Will Savage

Blood (2022) 140 (Supplement 1): 5352.

https://doi.org/10.1182/blood-2022-157810

Published: 2022

Journal Articles

DISC-0974, an Anti-Hemojuvelin Antibody, Reduces Hepcidin and Mobilizes Iron in Healthy Volunteers

Natasha Novikov, Akshay Buch, Hua Yang, Sarah Tuller, Michelle Andruk, Katherine Chan, Min Wu, Richard Rodriguez, Rajiv Panwar, Haley Howell, Brian MacDonald, Will Savage

Blood (2022) 140 (Supplement 1): 5339–5340.

https://doi.org/10.1182/blood-2022-167870

Published: 2022

Journal Articles

DISC-0974, an Anti-Hemojuvelin (HJV) Monoclonal Antibody, Reduced Hepcidin and Improved Anemia in a Rat Model of Chronic Kidney Disease

Min Wu, Kathryn Wang, Brian MacDonald

Blood (2022) 140 (Supplement 1): 8153–8154.

https://doi.org/10.1182/blood-2022-169552

Published: 2022

Journal Articles

Bitopertin, a Selective Glycine Transporter 1 Inhibitor, Reduced Protoporphyrin IX (PPIX) Level and Improved Liver Fibrosis in a Mouse Model of Erythropoietic Protoporphyria (EPP)

Min Wu, Sarah Ducamp, Yi Xiang, Juan Putra, Mark D. Fleming, Brian MacDonald, Paul J Schmidt

Blood (2022) 140 (Supplement 1): 8192–8193.

https://doi.org/10.1182/blood-2022-168924

Published: 2022

Journal Articles

DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Decreases Hepcidin and Increases Transferrin Saturation in a Non-Human Primate Model of Cytokine (IL-6) Induced Hypoferremia

Brian MacDonald, PhDMBBChir,MRCP, Cecile Blaustein, PhD, Sophia Nguyen, MS, Christopher King, PhD MBA, Vu Hong, PhD, Will Savage, MDPhD, Srikanth Venkatraman, PhD, Maria G. Beconi, PhD MS

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-138720

Published: 2020

Journal Articles

DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin

Vu Hong, PhD, Ravi Krishna Babu, PhD, Cecile Blaustein, PhD, Sophia Nguyen, MS, Venkateshwar Rao, PhD, Will Savage, MDPhD, Brian MacDonald, PhDMBBChir,MRCP, Maria G. Beconi, PhD MS, Srikanth Venkatraman, PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138509

Published: 2020

Journal Articles

Administration of Minihepcidins to Animals Affected By β-Thalassemia Major Reduces Anemia and Splenomegaly

Roberta Chessa, PhD, Ritama Gupta, MSc, Carla Casu, PhD, Robert E Fleming, MD, Yelena Ginzburg, Brian MacDonald, MB, ChB, PhD, Stefano Rivella, PhD

Blood (2016) 128 (22): 259.

https://doi.org/10.1182/blood.V128.22.259.259

Published: 2016

Journal Articles

Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera

Carla Casu, Paraskevi Rea Oikonomidou, Huiyong Chen, Vijay Nandi, Yelena Ginzburg, Princy Prasad, Robert E. Fleming, Yatrik M. Shah, Erika V. Valore, Elizabeta Nemeth, Tomas Ganz, Brian MacDonald, Stefano Rivella

Blood (2016) 128 (2): 265–276.

https://doi.org/10.1182/blood-2015-10-676742

Published: 2016

Includes: Supplemental data

Journal Articles

Concurrent Treatment with Minhepcidin and Deferiprone Improves Anemia and Enhances Reduction of Spleen Iron in a Mouse Model of Non-Transfusion Dependent Thalassemia

Carla Casu, PhD, Rea Oikonomidau, MD, Yatrik Shah, PhD, Elizabeta Nemeth, PhD, Tomas Ganz, MD PhD, Brian MacDonald, Stefano Rivella, PhD

Blood (2014) 124 (21): 748.

https://doi.org/10.1182/blood.V124.21.748.748

Published: 2014

Journal Articles

Use of Minihepcidins As a “Medical Phlebotomy” in the Treatment of Polycythemia Vera

Carla Casu, PhD, Rea Oikonomidau, MD, Elizabeta Nemeth, PhD, Tomas Ganz, MD PhD, Brian MacDonald, Stefano Rivella, PhD

Blood (2014) 124 (21): 3231.

https://doi.org/10.1182/blood.V124.21.3231.3231

Published: 2014

Journal Articles

Treatment With Minihepcidin Peptide Improves Anemia and Iron Overload In a Mouse Model Of Thalassemia Intermedia

Carla Casu, PHD, Adam Goldberg, Elizabeta Nemeth, PhD, Tomas Ganz, MD, PhD, Sara Gardenghi, PhD, Brian MacDonald, Stefano Rivella, PhD

Blood (2013) 122 (21): 431.

https://doi.org/10.1182/blood.V122.21.431.431

Published: 2013

NARROW

Phase 2, Randomized, Open-Label Trial of Bitopertin in Erythropoietic Protoporphyria: Beacon Trial Design

DISC-0974, an Anti-Hemojuvelin Antibody, Reduces Hepcidin and Mobilizes Iron in Healthy Volunteers

DISC-0974, an Anti-Hemojuvelin (HJV) Monoclonal Antibody, Reduced Hepcidin and Improved Anemia in a Rat Model of Chronic Kidney Disease

Bitopertin, a Selective Glycine Transporter 1 Inhibitor, Reduced Protoporphyrin IX (PPIX) Level and Improved Liver Fibrosis in a Mouse Model of Erythropoietic Protoporphyria (EPP)

DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Decreases Hepcidin and Increases Transferrin Saturation in a Non-Human Primate Model of Cytokine (IL-6) Induced Hypoferremia

DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin

Administration of Minihepcidins to Animals Affected By β-Thalassemia Major Reduces Anemia and Splenomegaly

Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera

Concurrent Treatment with Minhepcidin and Deferiprone Improves Anemia and Enhances Reduction of Spleen Iron in a Mouse Model of Non-Transfusion Dependent Thalassemia

Use of Minihepcidins As a “Medical Phlebotomy” in the Treatment of Polycythemia Vera

Treatment With Minihepcidin Peptide Improves Anemia and Iron Overload In a Mouse Model Of Thalassemia Intermedia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only